Add this topic to your myFT Digest for news straight to your inbox
Biogen’s aducanumab would be first new treatment in years for disease if approved by FDA
Scientists express scepticism of trial data and US regulatory process at fiery hearing
FDA staff give positive clinical review to what could be first new treatment in US for decades
Setback deals another blow to most common hypothesis about causes of the disease
Mylan had lodged dispute over a drug for multiple sclerosis
Biotech’s shares fluctuate as it tries to win over sceptics of aducanumab
Biogen says seeking approval for aducanumab hails ‘turning point’ in fight against disease
Biotech group says new analysis shows benefits of aducanumab when taken at a high dose
Treatments for multiple sclerosis and spinal muscular atrophy help Biogen beat forecasts
Drug company’s chief Michel Vounatsos says it has the cash for share buybacks and M&A
Biogen’s aducanumab was last hope of one approach to the disease, but there are others
Drugmaker loses $18bn from market value after deciding to discontinue trials
Patients on lower doses of its drug declined more quickly than those on a placebo
Shares in biotech group jump after promising results in Phase II trial
Large flows have recently also skewed GDP statistics for Ireland and Iceland
Biotech group stopped short of announcing large acquisition some expected
Pfizer among those risking backlash with new year increases on many medicines
Latest medicine to flunk late-stage trial raises questions over ‘amyloid hypothesis’
US stock markets push further into record territory ahead of Federal Reserve meeting
Dementia affects many millions but a cure is as elusive as ever
People with signs of ‘amyloid plaques’ on the brain could be treated before they develop symptoms
International Edition